Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer

BACKGROUND: In a phase II North American study (NP28761; NCT01871805), the anaplastic lymphoma kinase (ALK) inhibitor alectinib demonstrated both systemic and central nervous system (CNS) efficacy with good tolerability in patients with ALK-positive non-small cell lung cancer. We describe patient-re...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:ESMO Open
Asıl Yazarlar: Ou, Sai-Hong Ignatius, Socinski, Mark A, Gadgeel, Shirish, Gandhi, Leena, West, Howard, Chiappori, Alberto Alejandro, Cohen, Victor, Riely, Gregory J, Smoljanovic, Vlatka, Bordogna, Walter, Wright, Elaine, Debusk, Kendra, Zeaiter, Ali, Shaw, Alice T
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Publishing Group 2018
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6045737/
https://ncbi.nlm.nih.gov/pubmed/30018815
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2018-000364
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller